The effect of aspirin in primary stroke prevention is controversial in Western population, and no evidence is available in Asian population. We performed stroke subanalysis of the Japanese Primary Prevention Project (JPPP), which was a randomized controlled trial of aspirin vs no aspirin for primary prevention of vascular events in 14 464 patients aged over 60 years with hypertension, diabetes, and/or dyslipidemia. We evaluated the effects of aspirin on the risk of stroke and intracranial hemorrhage. Aspirin did not show any net benefit for primary stroke prevention during median follow-up for 5 years, because nonsignificant reduction in ischemic stroke was offset by nonsignificant increase in hemorrhagic stroke. Aspirin is not recommended for primary stroke prevention in elderly Japanese patients with vascular risk factors in general. Asymptomatic large artery atherosclerosis appears to be a new target for primary prevention of stroke.
cacy for primary stroke prevention, [2] [3] [4] and there is no evidence available for Asian population, which might have a different risk-benefit profile from that in Western population. However, hemorrhagic stroke is more likely to occur in Asian population than in Western population.
5,6
Based on these backgrounds, we performed stroke subanalysis of the Japanese Primary Prevention Project (JPPP), which was a randomized controlled trial of aspirin in elderly patients with vascular risk factors. 
| SUBJECTS AND METHODS
JPPP was an investigator-driven, nationwide, multicenter, open-label, randomized controlled trial of aspirin for primary prevention of vascular events. 7 Patients aged over 60 years with hypertension, diabetes, and/ or dyslipidemia were randomized to receive either 100 mg of aspirin or no aspirin and were followed for up to 6.5 years. A total of 14 464 patients were recruited, and the median follow-up period was 5.02 years.
We evaluated the effects of aspirin on fatal and nonfatal stroke, ischemic stroke plus transient ischemic attack (TIA), ischemic stroke, and intracranial hemorrhage (ICH) using exploratory Cox regression analyses. 
| RESULTS
Fatal and nonfatal strokes occurred in 128 patients in both the aspirin and no aspirin groups. No significant difference in the rate of any stroke or TIA at 5 years was observed between the two groups (2.068% in the aspirin group and 2.299% in the no aspirin group, adjusted hazard ratio [HR] 0.927, 95% confidence interval [CI] 0.741-1.160, P = .509) ( Figure 1A ). There was also no significant difference in any stroke at 5 years between both groups (1.809% in the aspirin group and 1.828% in the no aspirin group, adjusted HR 1.011, 95% CI 0.791-1.291, P = .932) This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
in the no aspirin group, but the difference was not significant (1.199% in the aspirin group and 1.451% in the no aspirin group, adjusted HR 0.842%, 95% CI 0.631-1.123, P = .240) ( Figure 1C ). Cumulative rate of ICH at 5 years was nonsignificantly higher in the aspirin group than in the no aspirin group (0.748% in the aspirin group and 0.511% in the no aspirin group, adjusted HR 1.463, 95% CI 0.956-2.237, P = .078) ( Figure 1D ). The details of ICH are shown in Table 1 . Cerebral hemorrhage occurred more frequently in the aspirin group than in the no aspirin group, whereas the rates of subarachnoid hemorrhage and subdural hematoma were comparable between the two groups.
Factors affecting stroke and TIA were evaluated using a Cox regression analysis in all patients recruited (Table 2) . Aspirin was not one of the factors affecting cerebrovascular events. Age over 70 years, cigarette smoking and diabetes mellitus were independent risk factors for cerebrovascular events. According to the estimated parameters, the risk score was calculated as a total of two for age over 70 years, one for smoking, and one for diabetes. A score of 0 or 1 was classified as low risk, and a score of two or more was classified as high risk. The cumulative rate of cerebrovascular events at 5 years was not different between the aspirin group and no aspirin group not only for the lowrisk patients but also for the high-risk patients ( Figure 2 ).
| DISCUSSION
Clinical trials conducted in Western countries have reported conflicting results regarding the benefit of aspirin for primary stroke F I G U R E 1 (A) Cumulative rates of any stroke or transient ischemic attack (TIA) in aspirin and no aspirin groups. There was no difference in the rates of stroke or TIA between the two groups. (B) Cumulative rate of any stroke in aspirin and no aspirin groups. There was no difference in the rate of stroke between the two groups. (C) Cumulative rate of ischemic stroke in aspirin and no aspirin groups. Ischemic stroke was nonsignificantly fewer in the aspirin group than in the no aspirin group. (D) Cumulative rate of intracranial hemorrhage (ICH) in aspirin and no aspirin groups. Rate of ICH was nonsignificantly higher in the aspirin than in the no aspirin group (Quoted from reference 8) Cerebral hemorrhage 28 15
Subarachnoid hemorrhage 10 8
Subdural hematoma 13 12
Other hemorrhage 1 1
prevention. [2] [3] [4] According to a meta-analysis reported by the Antithrombotic Trialists' Collaboration (ATT), aspirin did not reduce the risk of stroke for primary prevention 1 (Table 3) . However, the risk ratio of aspirin vs control was 0.95% (95% CI 0.85-1.06). Aspirin nonsignificantly reduced the risk of ischemic stroke (rate ratio 0.86, 95%
CI 0.74-1.00) but nonsignificantly increased the risk of hemorrhagic stroke (risk ratio 1.32, 95% CI 1.00-1.75).
We suspected that the risk-benefit profile of aspirin for primary stroke prevention might be different between Japanese and Western populations. In reality, the rate of ischemic stroke was lower in the JPPP population than in the ATT population for primary prevention (0.26%/y vs 1.04%/y), whereas the rate of hemorrhagic stroke was higher in the JPPP population than in the ATT population (0.08%/y vs 0.03%/y). 1, 8 However, the results of our subanalysis of stroke in the JPPP were similar to the results of the meta-analysis reported by ATT regarding the net benefit for primary stroke prevention. Therefore, we can conclude that aspirin does not reduce the risk of total stroke be- The relatively low rate of ischemic stroke may be attributable to well-controlled risk factors, as demonstrated in the baseline data.
7,8
However, despite the sufficient management of risk factors, hemorrhagic stroke was more common in the JPPP population than in the ATT population. The strongest risk factor for cerebral hemorrhage is widely recognized to be hypertension. [9] [10] [11] [12] [13] In the Secondary Prevention of Small Subcortical Strokes (SPS3) trial, the rate of hemorrhagic stroke was significantly reduced by a systolic blood pressure target of <130 mm Hg, compared with a systolic blood pressure target of 130 to 149 mm Hg in patients receiving aspirin alone or aspirin plus clopidogrel. 14 In the Bleeding with Antithrombotic Therapy (BAT) study, which was an observational cohort study in patients receiving antithrombotic drugs for cerebrovascular or cardiovascular diseases, the optimal cutoff blood pressure level to predict ICH was 130/81 mm Hg. In conclusion, aspirin did not have any net benefit for the primary prevention of strokes in elderly Japanese patients with risk factors.
Because, nonsignificant reduction in ischemic stroke was offset by nonsignificant increase in hemorrhagic stroke. Aspirin should be used for patients in whom a net clinical benefit, which is estimated by the total incidence of major ischemic and hemorrhagic events, can be ex- 
